Literature DB >> 21435698

Mortality and recurrence after treatment of VTE: long term follow-up of patients with good life-expectancy.

Marianne S Andresen1, Irene Sandven, Cathrine Brunborg, Anne Mette Njaastad, Finn Strekerud, Michael Abdelnoor, Pål Smith, Ulrich Abildgaard.   

Abstract

INTRODUCTION: After completed anticoagulant treatment for acute VTE, both the subsequent mortality and risk of recurrent VTE are high, probably related to the frequent presence of serious disease in these patients. The aim of the study was to determine survival and recurrence in selected patients with good life-expectancy, and to evaluate risk factors.
METHODS: The 323 patients were followed for median 7.4 years (range 4.1-11.9) after cessation of anticoagulation. Survival analysis and Cox-regression were used for univariate and multivariate analysis.
RESULTS: The cumulative incidence of survival after 5 years was 93.4%. Standardised mortality ratio was 1.42 for men and 1.28 for women. Patients without a transient risk factor prior to the index VTE were associated with higher risk of mortality compared to risk of mortality in patients with a transient risk factor (hazard ratio (HR) 2.81; 95% CI 1.40-5.62). Recurrence of VTE after 5 years was 19.0%. A persistent risk factor or a spontaneous VTE was associated with higher risk of recurrence compared to a transient risk factor (HR 2.39; 95% CI 1.44-3.95). Elevated D-dimer levels increased the risk, and immobilisation prior to the index VTE reduced the risk of recurrence. Sex, age and thrombophilia were not independent risk factors for recurrence.
CONCLUSIONS: Despite a low mortality rate in this selected cohort, the recurrence rate and risk factors for recurrence were similar to findings reported in unselected populations. VTE unrelated to a transient risk factor was associated with increased mortality compared to mortality in patients with a transient risk factor.
Copyright © 2011 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21435698     DOI: 10.1016/j.thromres.2011.02.017

Source DB:  PubMed          Journal:  Thromb Res        ISSN: 0049-3848            Impact factor:   3.944


  8 in total

Review 1.  Progress in the research on venous thromboembolism.

Authors:  Zhen Zhang; Liang Tang; Yu Hu
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2017-12-21

Review 2.  Epidemiology of venous thromboembolism.

Authors:  John A Heit
Journal:  Nat Rev Cardiol       Date:  2015-06-16       Impact factor: 32.419

Review 3.  The epidemiology of venous thromboembolism.

Authors:  John A Heit; Frederick A Spencer; Richard H White
Journal:  J Thromb Thrombolysis       Date:  2016-01       Impact factor: 2.300

4.  Risk Factors of Unfavorable Outcomes, Major Bleeding, and All-Cause Mortality in Patients with Venous Thromboembolism.

Authors:  Han Young Lee; Tae Hoon Yeo; Tae Kyung Heo; Young Gyu Cho; Dong Hui Cho; Kyung Bok Lee
Journal:  Vasc Specialist Int       Date:  2021-12-31

5.  Editorial: Highlights in Thrombosis: 2021.

Authors:  Colin E Evans
Journal:  Front Cardiovasc Med       Date:  2022-02-24

6.  Should lifelong anticoagulation for unprovoked venous thromboembolism be revisited?

Authors:  Otto Moodley; Hadi Goubran
Journal:  Thromb J       Date:  2015-10-05

7.  Population Pharmacokinetic and Pharmacodynamic Modeling Analysis of GCC-4401C, a Novel Direct Factor Xa Inhibitor, in Healthy Volunteers.

Authors:  H Y Choi; S Choi; Y H Kim; H S Lim
Journal:  CPT Pharmacometrics Syst Pharmacol       Date:  2016-08-11

8.  Allosteric Inhibition of Factor XIIIa. Non-Saccharide Glycosaminoglycan Mimetics, but Not Glycosaminoglycans, Exhibit Promising Inhibition Profile.

Authors:  Rami A Al-Horani; Rajesh Karuturi; Michael Lee; Daniel K Afosah; Umesh R Desai
Journal:  PLoS One       Date:  2016-07-28       Impact factor: 3.240

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.